BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc 2016;13 Suppl 4:S332-5. [PMID: 27564669 DOI: 10.1513/AnnalsATS.201507-436KV] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
2 Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res 2017;18:60. [PMID: 28416015 DOI: 10.1186/s12931-017-0543-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
3 Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of Precision Medicine in COPD. Mol Diagn Ther 2017;21:345-55. [PMID: 28247183 DOI: 10.1007/s40291-017-0266-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]